<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02764281</url>
  </required_header>
  <id_info>
    <org_study_id>XHLSG-NK-1602</org_study_id>
    <nct_id>NCT02764281</nct_id>
  </id_info>
  <brief_title>MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma</brief_title>
  <official_title>The Efficacy and Safety of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Chemotherapy (MEDA) With Autologous HSCT in the Treatment of Stage IV Natural Killer/T-Cell Lymphoma: A Multicenter, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of methotrexate, etoposide,
      pegaspargase and dexamethasone (MEDA) chemotherapy and autologous hematopoietic stem cell
      transplantation (Auto-HSCT) in patients with stage IV extranodal natural killer/T-cell
      lymphoma, nasal type.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extranodal natural killer/T-cell lymphoma (ENKTCL), nasal type, is a rare subtype of
      non-Hodgkin lymphoma (NHL) with relatively high incidence in China. L-asparaginase based
      chemotherapy improved overall response and prolonged the long-term survival for patients with
      stage IV. But the optimal treatment schedule has not been established. This study is designed
      with four cycles MEDA chemotherapy, followed by Auto-HSCT for stage IV patients with newly
      onset, relapsed or refractory diseases. The efficacy and safety of this protocol in the
      treatment of will be measured.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Day 28 of the 4th course of MEDA chemotherapy</time_frame>
    <description>The complete response rate will be assessed on day 28 of the 4th course of MEDA chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2-year</time_frame>
    <description>Progression free survival is the time from entry onto the treatment until lymphoma progression or death of any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Day 28 of the 4th course of MEDA chemotherapy</time_frame>
    <description>The overall response rate will be assessed on day 28 of the 4th course of MEDA chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>Day 1 of each course of chemotherapy and then every 3 months for 2 years</time_frame>
    <description>Treatment-Related Adverse Events will be assessed and graded by NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2-year</time_frame>
    <description>Overall survival is defiend as the time from entry onto the treatment until death of any reason</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Extranodal NK-T-Cell Lymphoma, Nasal Type</condition>
  <arm_group>
    <arm_group_label>MEDA/Auto-HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be initially treated with four cycles MEDA chemotherapy, followed by autologous hematopoietic stem cell transplantation (Auto-HSCT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDA</intervention_name>
    <description>Methotrexate, 3.0g/m2/d iv, day 1
Etoposide, 100mg/m2 iv, day 2 to day 4
Dexamethasone, 40mg/d iv, day 1 to day 4
Pegaspargase, 2500IU/m2/d im, day 4
The MEDA chemotherapy will be repeated every 3 weeks.</description>
    <arm_group_label>MEDA/Auto-HSCT</arm_group_label>
    <other_name>Methotrexate, Etoposide,Dexamethasone,Pegaspargase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Auto-HSCT</intervention_name>
    <description>Auto-HSCT will be performed with patients who responded to the initial MEDA chemotherapy with standard BEAM conditioning regimen.</description>
    <arm_group_label>MEDA/Auto-HSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pathological diagnosis of extranodal natural killer/T-cell lymphoma, nasal type based on
        WHO 2008 classification of tumors of haematopoietic and lymphoid tissue.

        Eastern Cooperative Oncology Group (ECOG ) performance status 0~3.

        Stage IV disease with at least one measurable lesion.

        Preserved organ functions for: Platelet&gt;20×109/L, hemoglobin&gt;60g/L, total bilirubin
        (TBIL)&lt;5×ULN, alanine transaminase (ALT)&lt;5×ULN, normal serum creatinine, fibrinogen≥0.5g/L,
        LVEF≥50%.

        No history of chemotherapy or radiotherapy for other solid cancers.

        Signed Informed consented.

        Exclusion Criteria:

        Relapsed or progressive disease within 6 months of prior L-asparaginase-based chemotherapy.

        Concurrent cancers need surgery or chemotherapy within 6 months.

        History of radiotherapy of upper-aero-digestive tract within last 3 months.

        Significant complications: LVEF≤50%, coagulopathy, autoimmune disease, severe infection, or
        liver cirrhosis, hemophagocytic lymphohistiocytosis.

        Mental disorders.

        Pregnant or lactation.

        HIV, hepatitis virus C (HCV), or active hepatitis virus B (HBV) infection with HBV DNA≥105
        copies/ml.

        History of pancreatitis.

        Known history for grade 3/4 allergy to the drugs in chemotherapy regimen.

        Enrolled in other trial treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rong Tao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Xinhua hospital, Shanghai Jiao Tong University of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rong Tao, MD</last_name>
    <phone>+86-21-25077603</phone>
    <email>hkutao@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Zhu, MD</last_name>
      <phone>+8621-23271699</phone>
      <email>zhuqi70@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Eye and ENT Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Ding, MD</last_name>
      <phone>+86-21-64377134</phone>
      <email>eentding@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Tao, MD</last_name>
      <phone>+86-21-25077603</phone>
      <email>hkutao@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Dong Fang hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hai-Feng Lan, MD</last_name>
      <phone>+8621-61569716</phone>
      <email>lanhf2013@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Tong Ren Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200336</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li-Gen Liu, MD</last_name>
      <phone>+86-21-52039999</phone>
      <email>liuligen@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xin Jiang People's Hospital</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-Yan Zhang, MD</last_name>
      <phone>+86-991-8562209</phone>
      <email>279222677@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Rong Tao</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

